##  [GGMON Communication 003/2021: Notification of Adverse Drug Events](/index%2Ephp/mandate/ggmon-communication-0032021-notification-of-adverse-drug-events) 

March 12, 2026

ANVISA encourages citizens and professionals to report adverse drug events via VigiMed and NOTIVISA to monitor the benefit-risk ratio of medications. Covers the global cost of adverse events ($42B annually per WHO), irrational use of medicines (over 50% used inappropriately), rational use principles, ANVISA's role in safety evaluation through risk management plans and international participation, and the importance of public and professional involvement in pharmacovigilance.



[Consult Now](/webform/consult%0A?url=https://www.freyrsolutions.com/index%2Ephp/markdownify/node/13117)



Source

[https://www.gov.br/anvisa/pt-br/centraisdeconteudo/publicacoes/monitoramento/fa…](https://www.gov.br/anvisa/pt-br/centraisdeconteudo/publicacoes/monitoramento/farmacovigilancia/comunicados-ggmon/comunicado-ggmon-003-2021/view)

 

 

Select Mandate HA

[ANVISA](/index%2Ephp/mandate-by-ha/anvisa)

 

Select Mandate Function

[Regulatory Affairs](/index%2Ephp/mandate-by-function/regulatory-affairs)